ArticleMedical oncology (Northwood, London, England)2009
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Article in Medical oncology (Northwood, London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Pooled it
- The prognostic value of phosphorylated Akt in breast cancer: a systematic review.Scientific reports · 2015Pooled it
- Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.PloS one · 2012Pooled it
- Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Trial
- Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Immunohistochemistry for PTEN testing in HR +/HER2- metastatic breast cancer.Virchows Archiv : an international journal of pathology · 2025Review
- Precise Immunodetection of PTEN Protein in Human Neoplasia.Cold Spring Harbor perspectives in medicine · 2019Review
- PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.PloS one · 2017Article
- Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.Journal of breast cancer · 2016Article
- Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer.Journal of breast cancer · 2015Article
- Primary trastuzumab resistance: new tricks for an old drug.Annals of the New York Academy of Sciences · 2010Article
- PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.The American journal of pathology · 2010Article
- PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.The Journal of molecular diagnostics : JMD · 2010Article
- Molecular basis for therapy resistance.Molecular oncology · 2010Review
- Immunohistochemical detection of phospho-Akt, phospho-BAD, HER2 and oestrogen receptors alpha and beta in Malaysian breast cancer patients.Pathology oncology research : POR · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The loss of PTEN and phosphorylated Akt (pAkt) expression is thought to be involved in the mechanism leading to trastuzumab resistance in patients with HER2-positive breast cancer. We retrospectively performed immunohistochemical analyses for estrogen receptor, progesterone receptor, HER2/neu, PTEN, pAkt, and p53 expression in tumor specimens obtained before and after trastuzumab-containing neo-adjuvant chemotherapy. The intensity of staining was evaluated for each biomarker, and the correlations between the immunohistochemical profiles and the clinical outcome were analyzed. The changes in the immunohistochemical profiles between specimens obtained before and after trastuzumab-containing neo-adjuvant chemotherapy were evaluated for patients with residual tumors. The present study included 44 patients with breast cancer who received trastuzumab-containing neo-adjuvant chemotherapy. Seventeen patients achieved a pathological complete response. The patients were positive for PTEN and pAkt (PTEN = 14%, N = 6/44; pAkt, 80%, N = 35/44). The expression of both PTEN and pAkt were not correlated with pathological complete response. Persistent HER2/neu over-expression after neo-adjuvant chemotherapy was significantly associated with recurrence. Among 27 patients with residual cancer, the percentages of patients with HER2/neu-positive or pAkt-positive tumors were low, but PTEN expression was elevated. The present study suggested that neither the immunohistochemical expression of PTEN nor the expression of pAkt was associated with the clinical outcome of trastuzumab-containing neo-adjuvant chemotherapy. Except among patients with pathological complete remission, the persistent over-expression of HER2/neu may be a poor prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.